Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Assets (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of Assets data on record, last reported at $1.7 billion in Q3 2025.

  • For Q3 2025, Assets rose 7.83% year-over-year to $1.7 billion; the TTM value through Sep 2025 reached $1.7 billion, up 7.83%, while the annual FY2024 figure was $1.6 billion, 4.27% up from the prior year.
  • Assets reached $1.7 billion in Q3 2025 per AMPH's latest filing, up from $1.6 billion in the prior quarter.
  • Across five years, Assets topped out at $1.7 billion in Q3 2025 and bottomed at $645.7 million in Q1 2021.
  • Average Assets over 5 years is $1.1 billion, with a median of $1.4 billion recorded in 2023.
  • Peak YoY movement for Assets: soared 112.56% in 2023, then grew 0.04% in 2024.
  • A 5-year view of Assets shows it stood at $671.5 million in 2021, then grew by 10.49% to $742.0 million in 2022, then skyrocketed by 103.9% to $1.5 billion in 2023, then increased by 4.27% to $1.6 billion in 2024, then increased by 5.63% to $1.7 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Assets were $1.7 billion in Q3 2025, $1.6 billion in Q2 2025, and $1.6 billion in Q1 2025.